Lupin gets USFDA nod to mkt generic cancer drug

New Delhi: Drug maker Lupin on Wednesday said it has received approval to market a cancer treatment drug in the US market.

The company has received approval from the US Food and Drug Administration (USFDA) for Lenalidomide Capsules in multiple strenghts, Lupin said in a statement.

Lenalidomide capsules are bioequivalent to Bristol-Myers Squibb Company’s Revlimid capsules, it added. The product will be manufactured at the drug maker’s Pithampur facility.

Lenalidomide capsules are indicated for the treatment of adult patients with various kinds of cancers, including multiple myeloma.